2 variant HBV, skal der til disse patienter overvejes yderligere eller alternativ behandling (se afsnit 5. 1).
If there is a loss of efficacy attributable to the emergence of YMDD variant HBV in these patients, additional or alternative therapies should be considered (see section 5.1).